Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes.
Thomas A CiullaJohn S PollackDavid F WilliamsPublished in: The British journal of ophthalmology (2020)
In clinical practice, patients with DMO undergo fewer anti-VEGF injections and exhibit worse visual gains compared with patients in randomised clinical trials. Visual outcomes correlate with treatment intensity at 1 year, with ceiling effects related to baseline VA.
Keyphrases
- clinical trial
- end stage renal disease
- optical coherence tomography
- clinical practice
- vascular endothelial growth factor
- endothelial cells
- newly diagnosed
- chronic kidney disease
- ejection fraction
- high intensity
- type diabetes
- open label
- prognostic factors
- randomized controlled trial
- double blind
- case report
- diabetic retinopathy
- stem cells
- study protocol
- phase ii
- metabolic syndrome
- adipose tissue
- patient reported
- insulin resistance
- placebo controlled
- skeletal muscle
- cell therapy
- wound healing